Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Analysis of inflammatory and metabolic biomarkers in patients submitted to abdominoplasty after bariatric surgery.

Modolin MLA, Cintra W Jr, Rocha RI, Camargo CP, Giuliani NR, Souza HP, Barbeiro HV, Gemperli R.

Acta Cir Bras. 2019;34(5):e201900506. doi: 10.1590/s0102-865020190050000006. Epub 2019 Jun 3.

2.

Novel targets for the treatment of relapsing multiple myeloma.

Giuliani N, Accardi F, Marchica V, Dalla Palma B, Storti P, Toscani D, Vicario E, Malavasi F.

Expert Rev Hematol. 2019 Jun 3:1-16. doi: 10.1080/17474086.2019.1624158. [Epub ahead of print]

PMID:
31125526
3.

Automatic Age Estimation and Majority Age Classification from Multi-Factorial MRI Data.

Stern D, Payer C, Giuliani N, Urschler M.

IEEE J Biomed Health Inform. 2018 Sep 24. doi: 10.1109/JBHI.2018.2869606. [Epub ahead of print]

PMID:
31059459
4.

A Preliminary Study Investigating Maternal Neurocognitive Mechanisms Underlying a Child-Supportive Parenting Intervention.

Giuliani NR, Beauchamp KG, Noll LK, Fisher PA.

Front Behav Neurosci. 2019 Feb 12;13:16. doi: 10.3389/fnbeh.2019.00016. eCollection 2019.

5.

A retained transcriptomic profile characterizes CD138+ cells in the short time progression from smoldering to active multiple myeloma.

Storti P, Agnelli L, Dalla Palma B, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N.

Haematologica. 2019 Mar 7. pii: haematol.2018.209999. doi: 10.3324/haematol.2018.209999. [Epub ahead of print]

6.

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients.

Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R, Ferretti E, Dalla Palma B, Vicario E, Accardi F, Mancini C, Martella E, Ribatti D, Vacca A, Pistoia V, Giuliani N.

Cancers (Basel). 2019 Mar 6;11(3). pii: E321. doi: 10.3390/cancers11030321.

7.

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts.

Muller J, Duray E, Lejeune M, Dubois S, Plougonven E, Léonard A, Storti P, Giuliani N, Cohen-Solal M, Hempel U, Thijssen VL, Beguin Y, Heusschen R, Caers J.

Cancers (Basel). 2019 Feb 23;11(2). pii: E261. doi: 10.3390/cancers11020261.

8.

Postmortem Imaging: An Update.

Cafarelli FP, Grilli G, Zizzo G, Bertozzi G, Giuliani N, Mahakkanukrauh P, Pinto A, Guglielmi G.

Semin Ultrasound CT MR. 2019 Feb;40(1):86-93. doi: 10.1053/j.sult.2018.10.012. Epub 2018 Oct 28. Review.

PMID:
30686372
9.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

10.

Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis.

Raimondo S, Saieva L, Vicario E, Pucci M, Toscani D, Manno M, Raccosta S, Giuliani N, Alessandro R.

J Hematol Oncol. 2019 Jan 8;12(1):2. doi: 10.1186/s13045-018-0689-y.

11.

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.

Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V, Malavasi F.

Front Immunol. 2018 Nov 28;9:2722. doi: 10.3389/fimmu.2018.02722. eCollection 2018. Review.

12.

Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience.

Tamburro FR, Castellan P, Neri F, Berardinelli F, Bada M, Sountoulides P, Giuliani N, Finazzi Agrò E, Schips L, Cindolo L.

Urologia. 2018 Nov;85(4):163-168. doi: 10.1177/0391560318759258. Epub 2018 Mar 28.

PMID:
30426883
13.

Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.

Toscani D, Bolzoni M, Ferretti M, Palumbo C, Giuliani N.

Front Immunol. 2018 Oct 24;9:2467. doi: 10.3389/fimmu.2018.02467. eCollection 2018. Review.

14.

Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis.

Petrusca DN, Toscani D, Wang FM, Park C, Crean CD, Anderson JL, Marino S, Mohammad KS, Zhou D, Silbermann R, Sun Q, Kurihara N, Galson DL, Giuliani N, Roodman GD.

J Hematol Oncol. 2018 Oct 4;11(1):123. doi: 10.1186/s13045-018-0666-5.

15.

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD.

Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, Giuliani N, Malavasi F.

Oncoimmunology. 2018 May 7;7(8):e1458809. doi: 10.1080/2162402X.2018.1458809. eCollection 2018.

16.

Predicting and Optimizing Microswimmer Performance from the Hydrodynamics of Its Components: The Relevance of Interactions.

Giuliani N, Heltai L, DeSimone A.

Soft Robot. 2018 Aug;5(4):410-424. doi: 10.1089/soro.2017.0099. Epub 2018 May 15.

17.

Neurofibromatosis type I and multiple myeloma coexistence: A possible link?

Accardi F, Marchica V, Mancini C, Maredi E, Racano C, Notarfranchi L, Martorana D, Storti P, Martella E, Palma BD, Craviotto L, Filippo M, Percesepe A, Aversa F, Giuliani N.

Hematol Rep. 2018 Apr 3;10(1):7457. doi: 10.4081/hr.2018.7457. eCollection 2018 Mar 2.

18.

Behavioral and neural correlates of parenting self-evaluation in mothers of young children.

Noll LK, Giuliani NR, Beauchamp KG, Fisher PA.

Soc Cogn Affect Neurosci. 2018 May 1;13(5):535-545. doi: 10.1093/scan/nsy031.

19.

The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38.

Bolzoni M, Toscani D, Costa F, Vicario E, Aversa F, Giuliani N.

Immunol Lett. 2019 Jan;205:65-70. doi: 10.1016/j.imlet.2018.04.007. Epub 2018 Apr 24. Review.

PMID:
29702149
20.

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis.

Accardi F, Papa V, Capozzi AR, Capello GL, Verga L, Mancini C, Martella E, Costa R, Notarfranchi L, Dalla Palma B, Aversa F, Pietrini V, Cenacchi G, Giuliani N.

Case Rep Hematol. 2018 Jan 31;2018:9840405. doi: 10.1155/2018/9840405. eCollection 2018.

21.

Neural predictors of eating behavior and dietary change.

Giuliani NR, Merchant JS, Cosme D, Berkman ET.

Ann N Y Acad Sci. 2018 Sep;1428(1):208-220. doi: 10.1111/nyas.13637. Epub 2018 Mar 15. Review.

PMID:
29543993
22.

Possible targets to treat myeloma-related osteoclastogenesis.

Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N.

Expert Rev Hematol. 2018 Apr;11(4):325-336. doi: 10.1080/17474086.2018.1447921. Epub 2018 Mar 9. Review.

PMID:
29495905
23.

Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide.

Aversa F, Bachar-Lustig E, Or-Geva N, Prezioso L, Bonomini S, Manfra I, Monti A, Schifano C, Zlotnikov-Klionsky Y, Martelli MF, Sammarelli G, Sassi M, Soli M, Giuliodori S, Benecchi M, Giuliani N, Lohr F, Pratissoli S, Reisner Y.

Blood Adv. 2017 Oct 30;1(24):2166-2175. doi: 10.1182/bloodadvances.2017009423. eCollection 2017 Nov 14.

24.

Role of Galectins in Multiple Myeloma.

Storti P, Marchica V, Giuliani N.

Int J Mol Sci. 2017 Dec 17;18(12). pii: E2740. doi: 10.3390/ijms18122740. Review.

25.

Perceptions of general and postpresidential election discrimination are associated with loss of control eating among racially/ethnically diverse young men.

Kelly NR, Smith TM, Hall GCN, Guidinger C, Williamson G, Budd EL, Giuliani NR.

Int J Eat Disord. 2018 Jan;51(1):28-38. doi: 10.1002/eat.22803. Epub 2017 Nov 17.

PMID:
29149497
26.

Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.

Dalla Palma B, Marchica V, Pedrazzoni M, Accardi F, Notarfranchi L, Goldoni M, De Luca F, Costa F, Storti P, Toscani D, Sammarelli G, Bonomini S, Aversa F, Giuliani N.

Br J Haematol. 2018 Dec;183(5):812-815. doi: 10.1111/bjh.15026. Epub 2017 Nov 16. No abstract available.

PMID:
29143308
27.

Factor XI gene variants in factor XI-deficient patients of Southern Italy: identification of a novel mutation and genotype-phenotype relationship.

Tiscia GL, Favuzzi G, Lupone MR, Cappucci F, Schiavulli M, Mirabelli V, D'Andrea G, Chinni E, Giuliani N, Caliandro R, Grandone E.

Hum Genome Var. 2017 Nov 9;4:17043. doi: 10.1038/hgv.2017.43. eCollection 2017.

28.

The Proteasome and Myeloma-Associated Bone Disease.

Accardi F, Toscani D, Costa F, Aversa F, Giuliani N.

Calcif Tissue Int. 2018 Feb;102(2):210-226. doi: 10.1007/s00223-017-0349-1. Epub 2017 Oct 28. Review.

PMID:
29080972
29.

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.

Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, Vescovini R, Mancini C, Martella E, Campanini N, Schifano C, Bonomini S, Accardi F, Horenstein AL, Aversa F, Malavasi F, Giuliani N.

Oncotarget. 2017 May 16;8(34):56598-56611. doi: 10.18632/oncotarget.17896. eCollection 2017 Aug 22.

30.

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties.

Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D, Accardi F, Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N.

Oncotarget. 2017 May 23;8(32):53053-53067. doi: 10.18632/oncotarget.18085. eCollection 2017 Aug 8.

31.

Volatile lipophilic substances management in case of fatal sniffing.

Romolo FS, di Luca NM, Ciallella C, Bottoni E, Fiore PA, Cappelletti S, Giuliani N, Augsburger M, Varlet V.

J Forensic Leg Med. 2017 Nov;52:35-39. doi: 10.1016/j.jflm.2017.08.005. Epub 2017 Aug 24.

PMID:
28850861
32.

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D'Anca M, Storti P, Samur MK, Ganan-Gomez I, Fulciniti MT, Mistry N, Jiang S, Bao N, Marchica V, Neri A, Bueso-Ramos C, Wu CJ, Zhang L, Liang H, Peng X, Giuliani N, Draetta G, Clise-Dwyer K, Kantarjian H, Munshi N, Orlowski R, Garcia-Manero G, DePinho RA, Colla S.

Cancer Cell. 2017 Jul 10;32(1):88-100.e6. doi: 10.1016/j.ccell.2017.05.011. Epub 2017 Jun 29.

33.

GPNA inhibits the sodium-independent transport system L for neutral amino acids.

Chiu M, Sabino C, Taurino G, Bianchi MG, Andreoli R, Giuliani N, Bussolati O.

Amino Acids. 2017 Aug;49(8):1365-1372. doi: 10.1007/s00726-017-2436-z. Epub 2017 May 17.

PMID:
28516268
34.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.

Perricone M, Palandri F, Ottaviani E, Angelini M, Bagli L, Bellesia E, Donati M, Gemmati D, Zucchini P, Mancini S, Marchica V, Trubini S, De Matteis G, Di Zacomo S, Favarato M, Fioroni A, Bolzonella C, Maccari G, Navaglia F, Gatti D, Toffolatti L, Orlandi L, Laloux V, Manfrini M, Galieni P, Giannini B, Tieghi A, Barulli S, Serino ML, Maccaferri M, Scortechini AR, Giuliani N, Vallisa D, Bonifacio M, Accorsi P, Salbe C, Fazio V, Gusella M, Toffoletti E, Salvucci M, Svaldi M, Gherlinzoni F, Cassavia F, Orsini F, Martinelli G.

Oncotarget. 2017 May 16;8(20):32608-32617. doi: 10.18632/oncotarget.15940.

35.

Neurodevelopmental changes across adolescence in viewing and labeling dynamic peer emotions.

Flannery JE, Giuliani NR, Flournoy JC, Pfeifer JH.

Dev Cogn Neurosci. 2017 Jun;25:113-127. doi: 10.1016/j.dcn.2017.02.003. Epub 2017 Feb 10.

36.

Presentation and validation of the DuckEES child and adolescent dynamic facial expressions stimulus set.

Giuliani NR, Flournoy JC, Ivie EJ, Von Hippel A, Pfeifer JH.

Int J Methods Psychiatr Res. 2017 Mar;26(1). doi: 10.1002/mpr.1553. Epub 2017 Jan 16.

PMID:
28090698
37.

IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N.

Haematologica. 2017 Apr;102(4):773-784. doi: 10.3324/haematol.2016.153841. Epub 2017 Jan 5.

38.

The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma.

Giuliani N, Chiu M, Bolzoni M, Accardi F, Bianchi MG, Toscani D, Aversa F, Bussolati O.

Expert Opin Ther Targets. 2017 Mar;21(3):231-234. doi: 10.1080/14728222.2017.1279148. Epub 2017 Jan 18. No abstract available.

PMID:
28052702
39.

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Horenstein AL, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V, Giuliani N, Malavasi F.

Mol Med. 2016 Dec;22:694-704. doi: 10.2119/molmed.2016.00198. Epub 2016 Oct 13.

40.

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Marchica V, Accardi F, Storti P, Mancini C, Martella E, Dalla Palma B, Bolzoni M, Todoerti K, Marcatti M, Schifano C, Bonomini S, Sammarelli G, Neri A, Ponzoni M, Aversa F, Giuliani N.

Int J Hematol. 2017 Jan;105(1):104-108. doi: 10.1007/s12185-016-2104-1. Epub 2016 Oct 3.

PMID:
27699576
41.

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, Guasco D, Todoerti K, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini PG, Neri A, Aversa F, Roodman GD, Giuliani N.

Leukemia. 2016 Dec;30(12):2351-2363. doi: 10.1038/leu.2016.137. Epub 2016 May 20.

PMID:
27311934
42.

Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.

Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N.

Blood. 2016 Aug 4;128(5):667-79. doi: 10.1182/blood-2016-01-690743. Epub 2016 Jun 6.

43.

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

Magarotto V, Bringhen S, Offidani M, Benevolo G, Patriarca F, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.

Blood. 2016 Mar 3;127(9):1102-8. doi: 10.1182/blood-2015-08-662627. Epub 2016 Jan 4. Erratum in: Blood. 2018 Mar 29;131(13):1495.

44.

The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.

Storti P, Toscani D, Airoldi I, Marchica V, Maiga S, Bolzoni M, Fiorini E, Campanini N, Martella E, Mancini C, Guasco D, Ferri V, Donofrio G, Aversa F, Amiot M, Giuliani N.

Haematologica. 2016 Mar;101(3):e107-10. doi: 10.3324/haematol.2015.133736. Epub 2015 Dec 11. No abstract available.

45.

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N.

Biomed Res Int. 2015;2015:172458. doi: 10.1155/2015/172458. Epub 2015 Oct 22. Review.

46.

The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.

Toscani D, Palumbo C, Dalla Palma B, Ferretti M, Bolzoni M, Marchica V, Sena P, Martella E, Mancini C, Ferri V, Costa F, Accardi F, Craviotto L, Aversa F, Giuliani N.

J Bone Miner Res. 2016 Apr;31(4):815-27. doi: 10.1002/jbmr.2741. Epub 2015 Dec 14.

47.

Blood monitoring of perfluorocarbon compounds (F-tert-butylcyclohexane, perfluoromethyldecalin and perfluorodecalin) by headspace-gas chromatography-tandem mass spectrometry.

Giuliani N, Saugy M, Augsburger M, Varlet V.

Talanta. 2015 Nov 1;144:196-203. doi: 10.1016/j.talanta.2015.05.015. Epub 2015 May 29.

PMID:
26452810
48.

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.

Palma BD, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F, Sammarelli G, Craviotto L, De Filippo M, Ruffini L, Omedè P, Ria R, Aversa F, Giuliani N.

Leukemia. 2016 Feb;30(2):409-16. doi: 10.1038/leu.2015.259. Epub 2015 Sep 30.

PMID:
26419509
49.

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.

Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, Marimpietri D, Bolzoni M, Toscani D, Oldham RJ, Cuccioloni M, Sasser AK, Pistoia V, Giuliani N, Malavasi F.

Cells. 2015 Sep 17;4(3):520-37. doi: 10.3390/cells4030520. Review.

50.

Prediction of daily food intake as a function of measurement modality and restriction status.

Giuliani NR, Tomiyama AJ, Mann T, Berkman ET.

Psychosom Med. 2015 Jun;77(5):583-90. doi: 10.1097/PSY.0000000000000187.

Supplemental Content

Loading ...
Support Center